Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| EnginZyme | 2024 | Non-equity Assistance | Undisclosed | Stockholm |
| Aledia | 2023 | Venture - Series Unknown | Undisclosed | Grenoble |
| HAYA Therapeutics | 2025 | Grant | Undisclosed | Lausanne |
| Inspirna | 2022 | Series D | Undisclosed | New York |
| CorVent Medical | 2024 | Grant | Undisclosed | Fargo |
| Ingenix | 2026 | Seed | $9.9M | Warsaw |
| ProQR Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Leiden |
| TISSIUM | 2026 | Series D | Undisclosed | Paris |
| One Biosciences | 2026 | Grant | $17.4M | Paris |
| P2 Science | 2026 | Venture - Series Unknown | Undisclosed | Woodbridge |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | EnginZyme | Non-equity Assistance | Undisclosed | Stockholm, Sweden |
| 2 | Aledia | Venture - Series Unknown | Undisclosed | Grenoble, France |
| 3 | HAYA Therapeutics | Grant | Undisclosed | Lausanne, Switzerland |
| 4 | Inspirna | Series D | Undisclosed | New York, United States |
| 5 | CorVent Medical | Grant | Undisclosed | Fargo, United States |
| 6 | Ingenix | Seed | $9.9M | Warsaw, Poland |
| 7 | ProQR Therapeutics | Post-IPO Equity | Undisclosed | Leiden, The Netherlands |
| 8 | TISSIUM | Series D | Undisclosed | Paris, France |
| 9 | One Biosciences | Grant | $17.4M | Paris, France |
| 10 | P2 Science | Venture - Series Unknown | Undisclosed | Woodbridge, United States |
EnginZyme is a biotechnology company that creates biomanufacturing techniques for the sustainable production of common goods.
Aledia develops and manufactures innovative light-emitting diodes (LEDs) based on a unique 3D architecture.
HAYA Therapeutics is a biotechnology company developing precision RNA-guided medicines that target the dark genome.
Inspirna is a biotechnology company developing drugs for the treatment of cancer.
We provide simple, sophisticated respiratory solutions for post-ICU and home environments, eliminating unnecessary cost and complexity.
Ingenix is building an AI Co-pilot for generating real-time hypotheses on clinical endpoints values and adverse events.
ProQR Therapeutics is a biotech company focused on developments of drugs to treat genetic disorders.
TISSIUM develops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery.
One Biosciences leverages single-cell technologies to identify new therapeutics for difficult-to-treat diseases.
P2 Science produces bio-based chemicals from renewable materials for consumer and industrial use.
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases.
DNA Script is a disruptive DNA synthesis company harnessing biology to accelerate breakthroughs in life science and human health.
Moon Surgical develops a new category of robotic surgery that enhances existing clinical practice with collaborative and adaptive robotics.
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
Elevara is a clinical-stage firm working on innovative therapies to treat rheumatoid arthritis and other chronic inflammatory disorders.
MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.
NanoPhoria develops non-viral, nano-delivery systems for cardiovascular treatments, focusing on inhalable biologics.
Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.
Actithera is a molecular radiotherapeutic company that develops radioligand therapies.
ENYO Pharma is a biopharmaceutical company based in Lyon, France.
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
SafeHeal develops Colovac, an innovative solution for the protection of digestive anastomosis, designed to reduce anastomotic complications.
We are making biology programmable to transform health and sustainability for the benefit of all.
Berry Street offers treatment for disordered eating, heart health, PCOD, liver disease, women's health, sports nutrition, and diabetes.
Leucid is progressing novel cart therapies that produce a better and more durable response.
Sofinnova Partners has invested in 116 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Sofinnova Partners's top investment sectors include Biotechnology, Health Care, Medical, Life Science, Therapeutics. The firm invests across 24 different industry categories.
Among tracked funding rounds, Hemab received $157.0M in a Series C round. Sofinnova Partners's total known invested capital is $4.1B.
Sofinnova Partners's average investment size is $53.1M across its portfolio of 116 companies.
Recent Sofinnova Partners portfolio additions include EnginZyme, Aledia, HAYA Therapeutics, Inspirna, CorVent Medical. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors